Smta Agreement

Material transfer agreements using the Standard Model are private agreements between the suppliers and recipients concerned, but the governing body is recognized by FAO as a third party beneficiary of the agreements. The standard template was developed to ensure that the provisions of the PGRFA transfer contract are applicable to users within the multilateral system. 23 June 2019: At a meeting of the Working Group on Access and Compensation for Plant Genetic Resources, progress was made on the list of crops and the revision of the Agreement on the Exchange of Material. The meeting was suspended to allow for further consultations before a Board of Directors in November 2019. In this category, WHO ensures access to products such as diagnostic test kits, additional products and resources for training. To date, agreements have been signed with two major diagnostic manufacturers that would provide WHO with a delivery of diagnostic kits and syringes during the next pandemic. To date, WHO has concluded 13 agreements with vaccine and antiviral manufacturers and, through this ATMS2, has guaranteed about four times the amount of pandemic vaccines available during the H1N1 pandemic. Among these signatories are 5 multinationals and the largest producer in developing countries. To date, WHO has concluded 71 agreements with academic and research institutes and, although this is not necessary, 29 have offered to contribute to the compensation of benefits. Most of them proposed to contribute to the strengthening of laboratory and surveillance capacities (training). Non-receptors for biological PIP must sign a MTS2 with WHO.

Shipments of PIP biological material (PIP) are accompanied by a shipping notification informing recipients that they must sign a SMTA2 in exchange for the use of the virus materials. A copy of this opinion is available below: the Working Group has made considerable progress on the specific provisions of the ATMS, with genetic sequence data and specific rates of payment on benefit compensation being the main outstanding issues. By entering into ATMS2s, these legally binding advance supply contracts ensure that WHO has predictable access to pandemic vaccines and other products. . . .